Diagnosis (WHO 2016)a |
MDS-RS | 6/14 (43%) |
MDS-SLD | 4/14 (29%) |
MDS-MLD | 3/14 (21%) |
MDS-del(5q) | 1/14 (7%) |
International Prognostic Scoring System (IPSS) |
IPSS score | 0.3 ± 0.4; 0 (0–1.0) |
Score = 0.0 | 8/14 (57%) |
Score = 0.5 | 3/14 (21%) |
Score = 1.0 | 3/14 (21%) |
Score > 1.0 | 0/14 (0%) |
IPSS risk groups |
Low risk | 8/14 (57%) |
Intermediate risk 1 | 6/14 (43%) |
Intermediate risk 2 | 0/14 (0%) |
High risk | 0/14 (0%) |
Cytogenetic based risk classificationb |
Very good | 0/10 (0%) |
Good | 9/10 (90%) |
Intermediate | 1/10 (10%) |
Poor | 0/10 (0%) |
Very poor | 0/10 (0%) |
- Abbreviations: IPSS International Prognostic Scoring System, MDS myelodysplastic syndromes, MDS-del(5q) MDS with isolated deletion of chromosome 5q, MDS-MLD MDS with multilineage dysplasia, MDS-RS MDS with ring sideroblasts, MDS-SLD MDS with single lineage dysplasia, WHO World Health Organization
- Results are expressed as absolute and (relative) frequencies
- a Patients with MDS unclassifiable or with ≥20% blast in the BM were omitted, as did patients with MDS with excess of blasts, and patients diagnosed with Myelodysplastic/myeloproliferative neoplasms
- b Cytogenetic scoring: Very good: -Y, del(11q); Good: normal, del(5q), del(12p), del(20q), double including del(5q); Intermediate: del(7q), + 8, + 19, i(17q), any other single or double independent clones; Poor: −7, inv.(3)/t(3q), del3q, double including − 7/del(7q), complex (3 abnormalities); Very poor: complex (> 3 abnormalities)